New Delhi, May 17 (IANS) The Indian biotech companies are actively developing mRNA-based vaccines and therapeutics, said a team of scientists at the Department of Biotechnology (DBT), under the Ministry of Science and Technology.
They were speaking at the 14th Webinar under the ‘Webinar Series on Biofoundry and Biomanufacturing Initiative’, along with Biotechnology Industry Research Assistance Council (BIRAC).
The session focused on “Biomanufacturing for mRNA Therapeutics”, a vital component under the BioE3 (Biotechnology for Economy, Environment and Employment) Policy.
“The BioE3 Policy’s vision is to foster high-performance biomanufacturing by supporting sustainable green growth. This approach marks a global shift toward sustainability, fuelling a ‘BioRevolution’ with the potential to reshape economies and societies,” said Dr. Alka Sharma, Senior Adviser/Sc ‘H’, DBT.
She also informed that the 14th Webinar in this series focuses on mRNA therapeutics, a key thematic subsector under the policy.
“Several Indian biotech companies and research institutions are actively involved in developing mRNA-based vaccines and therapeutics,” Sharma said, while also highlighting certain challenges plaguing the sector such as product delivery, product stability, and import dependence for raw materials.
Approved by the Union Cabinet and released by the Minister of Science and Technology, the BioE3 Policy aims to position India as a global leader in bio-based innovations.
It focuses on promoting sustainable biomanufacturing in diverse thematic areas including Precision Therapeutics such as mRNA therapeutics, supporting economic growth while promoting affordable healthcare accessible to the Indian population.
Dr. Varshneya Singh, Scientist ‘D’, DBT, provided an insightful overview of the mRNA therapeutics subsector.
“mRNA-based therapies represent a groundbreaking advancement in biotechnology, with the potential to tackle a broad spectrum of diseases, including cancer, genetic conditions, and infectious diseases,” Singh said.
He provided a SWOT analysis of the subsector, identifying its strengths, weaknesses, opportunities, and threats.
Dr. Raghavan Varadarajan, IISc Bangalore explored cutting-edge advances in mRNA-LNP vaccine technology, emphasising its revolutionary role in modern medicine.
He talked about the mRNA vaccine design workflow; major advantages of mRNA vaccine modality; key structural elements of mRNA; workflow for LNP preparation, comparative analysis of different mRNA-LNP formulations, different kinds of microfluidic chips used, and comparison of different formulation methods.
The Webinar served as a collaborative forum, bringing together academia, industry experts, start-ups, and researchers to explore the latest developments and emerging opportunities in the field of mRNA therapeutics biomanufacturing.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
